Carregant...
Exosomal PD-L1: Roles in tumor progression and immunotherapy
The use of immune checkpoint therapies targeting programmed death-1 (PD-1) and its ligand (PD-L1) continue to show limited, durable success in clinical cases, despite widespread application. While some patients achieve complete responses and disease remission, others are completely resistant to the...
Guardat en:
| Publicat a: | Trends Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330176/ https://ncbi.nlm.nih.gov/pubmed/32610067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2020.03.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|